Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Forty51 Ventures is a biotech venture creator founded in April 2022 and is headquartered in Basel, Switzerland. The firm is dedicated to building and investing in early-stage biotech companies throughout Europe. Their mission centers on supporting entrepreneurs in developing innovative biotech solutions that have a clear path to clinical application.
Since its inception, Forty51 Ventures has focused on creating a portfolio of companies that address significant unmet medical needs. The firm operates with a therapeutic area agnostic approach, allowing them to explore various opportunities within the biotech sector. Their commitment to fostering innovation in healthcare is evident in their investment strategy and the expertise of their team.
Forty51 Ventures invests in early-stage biotech opportunities, primarily targeting therapeutic areas such as central nervous system (CNS) disorders, oncology, immunology and inflammation, fibrotic disorders, and ophthalmology. The firm engages in both single-asset and platform investments, which allows them to diversify their portfolio while concentrating on impactful biotech solutions.
The firm’s investment strategy emphasizes a clear path to clinical application, ensuring that the companies they support are not only innovative but also viable in the healthcare market. This focus on early-stage investments positions Forty51 Ventures as a key player in the European biotech landscape.
Sascha Oliver Bucher - Co-Founder and Partner. Sascha has extensive experience in the biotech sector, focusing on early-stage investments and company building.
Sara Núñez-García - Co-Founder and Partner. Sara brings a wealth of knowledge in biotech and healthcare, with a strong background in investment strategies.
Tamás Schweighoffer - Co-Founder and Partner. Tamás has a proven track record in biotech investments and operational support for startups.
Alan S. Roemer - Strategic Partner, USA. Alan provides insights into the U.S. biotech market, enhancing Forty51 Ventures' international reach.
Darren Ji - Advisor. Darren offers expertise in biotech strategy and investment.
Jonathan Knowles - Advisor. Jonathan has a strong background in biotech research and development.
Hans Schikan - Advisor. Hans brings extensive experience in the pharmaceutical industry and strategic guidance.
Bill Symonds - Advisor. Bill provides insights into market trends and investment opportunities in biotech.
Peter van Vlasselaer - Advisor. Peter has a strong background in biotech and healthcare investments, contributing to the firm's strategic direction.
Founders interested in pitching to Forty51 Ventures should send their proposals via email to info@forty51ventures.com. A well-structured pitch deck that includes key information about the startup, market opportunity, and clinical pathway is recommended.
What are the investment criteria for Forty51 Ventures?
Forty51 Ventures focuses on early-stage biotech companies that demonstrate a clear path to clinical application. They are particularly interested in therapeutic areas such as CNS disorders, oncology, immunology and inflammation, fibrotic disorders, and ophthalmology.
How can founders pitch to Forty51 Ventures?
Founders can reach out to Forty51 Ventures via email at info@forty51ventures.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and clinical pathway.
What makes Forty51 Ventures different from other biotech investors?
The firm is dedicated to building and investing in companies with a clear clinical application, which sets them apart from many investors who may focus solely on financial returns. Their therapeutic area agnostic approach allows for flexibility in investment opportunities.
What is the geographic focus of Forty51 Ventures?
Forty51 Ventures primarily invests in early-stage biotech companies located in Europe, allowing them to leverage local expertise and market knowledge.
What is the typical check size for investments?
While specific check sizes are not disclosed, Forty51 Ventures focuses on pre-seed, seed, and Series A stages, which typically involve smaller initial investments that can grow as companies develop.
What kind of support do portfolio companies receive?
Forty51 Ventures provides operational support and strategic guidance to their portfolio companies, helping them navigate the complexities of the biotech industry and enhancing their chances of success.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.